Jeff Jonas
Chief Executive Officer, Sage Therapeutics
Meet Jeff Jonas
Jeff joined Sage as CEO in 2013 and has more than 20 years of experience in the pharmaceutical and healthcare industries. In 2019, the FDA approved Sage’s brexanolone injection, the first new drug specifically indicated for women with postpartum depression.